Conferences - Results from #440

ASCO GU 2025: Lutetium-177 PSMA Radioligand Therapy in Taxane-Naïve First- and Second-Line Metastatic Castration Resistant Prostate Cancer After First-Line ARPI Therapy February 14, 2025

ASCO GU 2025: Grade and Volume Progression and Its Association with the Decipher® Genomic Classifier Using Patients Enrolled in a Prospective Active Surveillance Protocol February 14, 2025

ASCO GU 2025: Real-World Comparison of Cabazitaxel vs. 177-Lutetium-PSMA Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer February 14, 2025

ASCO GU 2025: Cancer-Control Outcomes of Metastatic Castration Resistant Prostate Cancer Patients with BRCA-Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium PSMA Radioligand Therapy. February 14, 2025

ASCO GU 2025: Expanded Access Program of Cretostimogene Grenadenorepvec in Patients with NMIBC Unresponsive to BCG February 14, 2025

ASCO GU 2025: Preliminary Results from LEGEND: A Phase 2 Study of Detalimogene Voraplasmid (EG-70), a Novel, Non-Viral Intravesical Gene Therapy for Patients with BCG-Unresponsive NMIBC with CIS February 14, 2025

ASCO GU 2025: ABLE-32: A Randomized, Controlled, Phase 3b Clinical Trial of Nadofaragene Firadenovec-Vncg Versus Observation in Patients With Intermediate-Risk NMIBC February 14, 2025

ASCO GU 2025: Decipher® Risk Stratification of Radiorecurrent Prostate Cancer: Correlative Analysis of the F-SHARP Trial of Salvage Reirradiation February 14, 2025

ASCO GU 2025: CORE-008: A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study To Evaluate Intravesical Cretostimogene Grenadenorepvec in Participants With High-Risk NMIBC February 14, 2025

ASCO GU 2025: Efficacy of 177Lu-PSMA-617 with or Without Androgen Receptor Pathway Inhibitors for the Treatment of mCRPC: VISION Secondary Analysis February 14, 2025

ASCO GU 2025: Evaluating Associations Between Genomic Classifier and Digital Pathology–based Multi-Modal AI Biomarkers in Oligometastatic Castration-Sensitive Prostate Cancer February 14, 2025

ASCO GU 2025: Final Overall Survival with Talazoparib + Enzalutamide as First-line Treatment in Patients with HRR-deficient mCRPC in the Phase 3 TALAPRO-2 Trial February 14, 2025

ASCO GU 2025: Effectiveness and Safety of Radium-223 in Men with mCRPC: A Systematic Literature Review of 48 Real-world Studies February 14, 2025

ASCO GU 2025: Initial Report of a Randomized Trial of Post-Prostatectomy Prostate Cancer Radiotherapy Using Either Fluciclovine (18F) or PSMA (68Ga) PET/CT for Target Dose-Escalation February 14, 2025

ASCO GU 2025: PSA Response to 177Lu-PSMA-617 in Patients Experiencing Xerostomia and Ocular Dryness in mCRPC February 14, 2025

ASCO GU 2025: Real-World Treatment Patterns and Outcomes in Advanced Prostate Cancer: A Cohort Study Using the Prostate Cancer Disease Observation (PRECISION) Data Platform February 14, 2025

ASCO GU 2025: Intra-Patient Comparison of Urinary Radioactivity After 18F-Piflufolastat and 18F‑flotufolastat PET in Men with Low PSA Biochemical Recurrence of Prostate Cancer Who Have Had Radical Prostatectomy February 14, 2025

ASCO GU 2025: COBRA: Assessment of the Efficacy of 64Cu-SAR-bisPSMA Using Histopathology as Reference Standard in Patients with Biochemical Recurrence of Prostate Cancer Following Definitive Therapy February 14, 2025

ASCO GU 2025: COGCaP - Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Cancer of the prostate: A Comparison of Enzalutamide vs Abiraterone Acetate February 14, 2025

ASCO GU 2025: Real World Outcomes of 177Lu-PSMA-617 in a Racially Diverse Cohort of Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) February 14, 2025

Page 23 of 621